cd22 car-transduced t cells
Refractory Childhood Non-Hodgkin Lymphoma
Sumithira VasuCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Refractory Childhood Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sumithira Vasu | Phase 1 | CC |
Anti-Cd19/Cd20/Cd22 Car T-Cells Sumithira Vasu | Phase 1 | CC |
Cyclophosphamide Sumithira Vasu | Phase 1 | CC |
Same molecule, other indications
cd22 car-transduced t cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →